Previous close | 373.90 |
Open | 368.95 |
Bid | 372.05 x 0 |
Ask | 373.45 x 0 |
Day's range | 368.95 - 368.95 |
52-week range | 300.00 - 409.25 |
Volume | |
Avg. volume | 2 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
On May 2, 2024, Director Sangeeta Bhatia sold 467 shares of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) as reported in a recent SEC Filing.
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $400.16, representing a -0.49% change from its previous close.
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.